High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...
Zacks.com on MSN4d
AbbVie Falls 8% in 3 Months: Buy, Hold or Sell the Stock?Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Other drugs in AbbVie's lineup, including Botox, migraine therapies Qulipta and Ubrelvy, cancer drug Venclexta, and antipsychotic medication Vrayalar, are also delivering strong sales growth.
According to GlobalData, Qulipta has the edge when it comes to data on migraine prevention rates and has a broader range of available doses. Biohaven said in its first quarter statement that it is ...
AbbVie’s oral CGRP inhibitor Qulipta (atogepant) is also under review by NICE for migraine prevention, with a decision due in mid-August. “On top of debilitating physical symptoms, migraine ...
After hours: 7:59:44 pm GMT-5 ...
Pre-Market: 8:29:06 a.m. EST ...
After hours: 7:58:27 pm GMT-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback